WO2018001895A1 - Microcapsules encapsulating lambda-cyhalothrin - Google Patents

Microcapsules encapsulating lambda-cyhalothrin Download PDF

Info

Publication number
WO2018001895A1
WO2018001895A1 PCT/EP2017/065541 EP2017065541W WO2018001895A1 WO 2018001895 A1 WO2018001895 A1 WO 2018001895A1 EP 2017065541 W EP2017065541 W EP 2017065541W WO 2018001895 A1 WO2018001895 A1 WO 2018001895A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
weight
microcapsule
cyhalothrin
lambda
Prior art date
Application number
PCT/EP2017/065541
Other languages
English (en)
French (fr)
Inventor
Kal EDLY
Matthew Robert COTTLE
Original Assignee
Syngenta Participations Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES17732136T priority Critical patent/ES2966395T3/es
Priority to BR112018077181-3A priority patent/BR112018077181B1/pt
Priority to PL17732136.1T priority patent/PL3478063T3/pl
Priority to HRP20231633TT priority patent/HRP20231633T1/hr
Priority to EA201990133A priority patent/EA201990133A1/ru
Priority to US16/312,832 priority patent/US20190350196A1/en
Priority to CN201780040443.5A priority patent/CN109414015A/zh
Priority to MX2018016035A priority patent/MX2018016035A/es
Application filed by Syngenta Participations Ag filed Critical Syngenta Participations Ag
Priority to EP17732136.1A priority patent/EP3478063B1/en
Priority to KR1020197001818A priority patent/KR102513421B1/ko
Priority to UAA201900761A priority patent/UA128382C2/uk
Publication of WO2018001895A1 publication Critical patent/WO2018001895A1/en
Priority to PH12018502597A priority patent/PH12018502597A1/en
Priority to CONC2018/0013652A priority patent/CO2018013652A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/26—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests in coated particulate form
    • A01N25/28—Microcapsules or nanocapsules
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N53/00—Biocides, pest repellants or attractants, or plant growth regulators containing cyclopropane carboxylic acids or derivatives thereof

Definitions

  • the present invention relates to certain compositions comprising microcapsules encapsulating a pyrethroid insecticide, and methods of controlling damage on plants with such compositions.
  • Microencapsulation of pesticides and other agricultural chemicals has been performed for a number of years, using various microencapsulation processes or techniques, and in connection with a number of different active ingredients.
  • WO 97/44125 describes that pyrethroids, particularly lambda-cyhalothrin, when used for foliar application, should be encapsulated because of its risks to workers, but also the capsules should be such that lambda-cyhalothrin is relatively quick released for control of the target foliar pests.
  • WO 97/44125 teaches that a polyurea wall made from a certain mixture of isocyanates in a defined ratio would be preferred.
  • microcapsules encapsulating pyrethroids should indeed have a specific defined polyurea wall, but the wall properties now found to be desirable are contradictory to the wall properties described in W097/44125, in particular to provide improved worker exposure characteristics, such as an improved toxicology profile,, whilst still maintaining effective pest control activity.
  • the present invention provides a composition
  • a composition comprising a microcapsule having a polyurea wall encapsulating a pyrethroid insecticide, preferably lambda- cyhalothrin, wherein the polyurea wall of the microcapsule is made of polyurea polymers derived from a mixture of aromatic polyisocyanate (A) and aromatic diisocyanate (B), the weight ratio of (A) to (B) is about 1 :1 , the polymer (or wall) content of each microcapsule is from about 6 to about 9, preferably about 7 to about 8, % by weight, and the amount of the pyrethroid insecticide, preferably the lambda-cyhalothrin, is from about 15 to about 60, preferably about 20 to about 55, % by weight, each based on the weight of the microcapsule.
  • the present invention provides an aqueous composition comprising the composition of the first aspect, provided the composition does not contain one or more of: an active ingredient having a melting point at 25°C of less or equal to 50°C; an active ingredient in salt form, and a free or dispersed hydrophobic oil phase.
  • the present invention provides a composition comprising an aqueous composition of the first or second aspect and one or more other active ingredients.
  • the present invention provides a method for controlling damage to a plant by a pest comprising applying an effective amount of a composition of each of the aspects of the invention to the pest, to the plant, or to its locus thereof.
  • the pyrethroid insecticide is lambda-cyhalothrin.
  • the pyrethroid insecticide is present in the core of the capsules, and in the case of lambda- cyhalothrin, it is dissolved in the organic solvent.
  • the d50 median diameter of the microcapsule in the composition is from about 0.5 to about 5, preferably about 1 to about 4, microns.
  • the amount of the microcapsules in the composition is from about 45 to about 55, preferably about 47 to about 53, % by weight, based on the weight of the composition.
  • the pyrethroid is present in an amount of from about 20 to about 55, preferably about 40 to about 50, more preferably about 43 to about 47, % by weight, based on the weight of the microcapsule.
  • the organic phase also comprises dispersed titanium dioxide particles having a d50 median particle size diameter of about 0.1 to about 0.6, preferably about 0.15 to about 0.5, microns, and are present in an amount of from about 3 to about 7, preferably about 3.5 to about 6, % by weight, based on the weight of the microcapsule.
  • the aromatic polyisocyanate is polymethylene polyphenylisocyanate and the aromatic diisocyanate is toluene diisocyanate, preferably an isomeric mixture of toluene diisocyanate, such as about 80% 2,4-isomer and about 20% 2,6-isomer of toluene diisocyanate.
  • the composition comprises a microcapsule having a polyurea wall encapsulating lambda-cyhalothrin and dispersed titanium dioxide particles, wherein the polyurea wall of the microcapsule is made of polyurea polymers derived from a mixture of polymethylene polyphenylisocyanate (A) and an isomeric mixture of toluene diisocyanate (B), provided that the d50 median particle size diameter of the titanium dioxide particles is from about 0.15 to about 0.5 microns, the d50 median diameter of the microcapsule in the composition is from 1 to 4, microns, the weight ratio of (A) to (B) is about 1 :1 , the polymer (or wall) content of each microcapsule is from about 7 to about 8, % by weight, the amount of titanium dioxide is present in an amount of from about 3.5 to about 6, % by weight, and the amount of the lambda-cyhalothrin, is from about 40 to about 50, % by weight,
  • the process involves encapsulation of a water immiscible material (in the present case preferably an organic phase containing a pyrethroid insecticide) within discrete capsules of polyurea.
  • a water immiscible material in the present case preferably an organic phase containing a pyrethroid insecticide
  • hydrolysis of an isocyanate monomer to form an amine via a carbamic acid intermediate occurs, and that in turn reacts with another isocyanate monomer to form the polyurea.
  • the process comprises two stages.
  • a physical dispersion of a water-immiscible phase in an aqueous phase is prepared.
  • the water-immiscible phase comprises the pesticide to be encapsulated together with other material as described below.
  • the dispersion is produced by a high shear device, and this step is carried out until the desired droplet size (as discussed below) is obtained. Only mild agitation is required for the remainder of the process.
  • the dispersion is stirred under high shear and maintained at a temperature range of from about 20°C to about 90°C, during which reaction occurs involving the organic diisocyanate and organic polyisocyanate to form the polyurea at the interfaces between the droplets of the organic phase and the aqueous phase. Adjustment of the pH of the resulting mixture and the temperature range during the second stage advance this condensation reaction.
  • the aqueous phase is prepared from water, a protective colloid, and preferably a surfactant.
  • the surfactant or surfactants in this phase may be anionic or nonionic surfactants with an HLB range of from about 12 to about 16. If more than one surfactant is used, individual surfactants may have HLB values lower than 12 or higher than 16 as long as the overall HLB value of the combined surfactants will be within the range of about 12 to 16.
  • Suitable surfactants include polyethylene glycol ethers of linear alcohols, ethoxylated
  • nonylphenols nonylphenols, naphthalene sulfonates, salts of long chain alkyl benzene sulfonates, block copolymers of propylene and ethylene oxides, anionic/nonionic blends, and the like.
  • the hydrophobic portion of the surfactant has chemical characteristics similar to the water- immiscible phase.
  • one suitable surfactant would be an ethoxylated nonylphenol.
  • Particularly preferred surfactants include block copolymers of propylene oxide and ethylene oxide, and anionic/nonionic blends.
  • the protective colloid present in the aqueous (or continuous) phase must absorb strongly onto the surface of the oil droplets and can be selected from a wide range of such materials including polyacrylates, methyl cellulose, polyvinyl alcohol, polyacrylamide, poly (methylvinyl ether/maleic anhydride), graft copolymers of polyvinyl alcohol and methylvinyl ether/maleic acid [hydrolyzed methyl vinyl ether/maleic anhydride (see U.S. Patent 4,448,929, which is hereby incorporated by reference herein)]; and alkali metal or alkaline earth metal lignosulfonates.
  • the protective colloid is selected from alkali metal and alkaline earth metal lignosulfonates, most preferably sodium lignosulfonates, such as
  • TERGITOLTM NP7 Tergitol XD, Tergitol NP40, Tergitol 15-S-20, WITCONATETM 90.
  • the range of surfactant concentration in the process is from about 0.01 to about 10.0 percent by weight, based on the aqueous phase, but higher concentrations of surfactant may also be used.
  • the protective colloid is generally present in the aqueous phase in an amount of from about 0.1 to about 5.0 percent by weight.
  • the amount of protective colloid employed will depend on various factors, such as molecular weight, compatibility, etc., so long as enough is present to completely coat the surfaces of all the oil droplets.
  • the protective colloid can be added to the aqueous phase prior to the addition of the organic phase, or can be added to the overall system after the addition of the organic phase or the dispersion of it.
  • the surfactants should be chosen so as to not displace the protective colloid from the droplet surfaces.
  • the organic phase comprises the pyrethoid to be encapsulated, one or more solvents, an aromatic diisocyanate and an aromatic polyisocyanate.
  • Suitable solvents include aromatic hydrocarbons such as xylenes, naphthalenes, or mixtures of aromatics; aliphatic or
  • cycloaliphatic hydrocarbons such as hexane, heptane and cyclohexane; alkyl esters including alkyl acetates and alkyl phthalates, ketones such as cyclohexanone or acetophenone, chlorinated hydrocarbons, vegetable oils, or mixtures of two or more such solvents.
  • the pyrethroid is lambda-cyhalothrin and is dissolved in the organic solvent.
  • titanium dioxide particles are comprised in the organic phase too, as well as dispersants used in dispersing the particles.
  • the dispersants useful for dispersing the titanium dioxide particles are certain non-ionic surfactants which act by steric hindrance and are active only at the protectant solid/organic liquid interface and do not act as emulsifying agents.
  • Such dispersants are suitably made up of (a) a polymeric chain having a strong affinity for the liquid and (b) a group which will absorb strongly to the solid.
  • dispersants examples include those of the HYPERMERTM and ATLOXTM lines, including Hypermer PS1 , Hypermer PS2, Hypermer PS3, Atlox LPI, Atlox LP2, Atlox LP4, Atlox LP5, Atlox LP6, and Atlox 4912; and AGRIMERTM polymers such as Agrimer AL-216 and AL-220.
  • microcapsules are obtained providing improved work exposure characteristics (such as improved toxicology profile, e.g., at least one of better oral, dermal, and inhalation toxicity, improved skin and eye irritation, and a better skin sensitizer), but which are still relatively quickly released when applied in an agricultural environment.
  • improved work exposure characteristics such as improved toxicology profile, e.g., at least one of better oral, dermal, and inhalation toxicity, improved skin and eye irritation, and a better skin sensitizer
  • the walls are formed only of a mixture of aromatic diisocyanates with an aromatic polyisocyanate, in which the weight ratio of polyisocyanate to diisocyanate is about 1 :1 .
  • diisocyanate and the polyisocyanates which may be used in this invention are those described in U.S. Patent 4,285,720.
  • Diisocyanates usable in the process of this invention include m-phenylene diisocyanate, p-phenylene diisocyanate; 1 -chloro-2,4-phenylene diisocyanate; 4,4'-methylenefc>/s(phenyl isocyanate); 3,3'-dimethyl-4,4' -biphenylene
  • Aromatic polyisocyanates usable in this invention have 3 or more isocyanate groups and include polymethylene polyphenylisocyanate, triphenylmethane triisocyanate (DESMODURTM R) and the adduct formed between 1 mole of trimethylolpropane and 3 moles of tolulene diisocyanate ("Desmodur TH").
  • the total amount of organic isocyanates used in the process will determine the wall content of the microcapsules formed.
  • the isocyanates (and correspondingly the microcapsule walls formed from them) will comprise from about 6 to about 9 percent by weight of the microcapsule, preferably from about 7 to about 8 percent by weight.
  • the size of the microcapsules produced which corresponds to the droplet size of the organic phase in the oil-in-water emulsion, is about d50 median diameter of from 0.5 to 5, preferably 1 to 4, microns.
  • the droplet size can be adjusted by the stirring speed and time, and by the type and amount of surfactant employed, as generally known in the art.
  • the organic phase is added to the aqueous phase with stirring.
  • a suitable dispersing means is employed to disperse the organic phase in the aqueous phase. This means may be any high shear device, operated so as to obtain the desired droplet (and corresponding microcapsule particle) size within the range of about 0.5 to about 5, preferably about 1 to about 4 microns. Once the proper droplet size is obtained, the dispersion means is discontinued and only mild agitation is required for the remainder of the process.
  • the temperature of the two-phase mixture is then raised from ambient to a value of from about 20°C to about 90°C, preferably about 40°C to about 90°C.
  • the pH value may be adjusted to an appropriate level.
  • the microencapsulated composition of the present invention may also contain conventional formulation aids, such as bactericides, antifoams, antifreeze agents, pH adjusters, buffers and viscosity control agents.
  • the present invention provides a process for preparing a composition as defined in the first aspect, which process comprises the steps of (a) preparing an organic phase comprising a pyrethroid insecticide, preferably lambda-cyhalothrin, to be encapsulated, aromatic polyisocyanate (A), aromatic diisocyanate (B), wherein the weight ratio of the (A) to (B) is 1 :1 , and optionally titanium dioxide particles having d50 median particle size of 0.1 to about 0.6, preferably 0.15 to about 0.5, microns, dispersed in the organic phase by means of a dispersant; (b) introducing the organic phase into an aqueous phase comprising water, a protective colloid, and optionally a surfactant to form a dispersion of the organic phase in the aqueous phase; (c) mixing the dispersion under high shear to form an oil-in-water emulsion in which the oil droplets of the emulsion have a d
  • the microencapsulated formulation of the invention is an aqueous formulation containing capsules and so would have the formulation designation code CS.
  • microencapsulated formulations of the present invention are storage stable and have acceptable handling characteristics, so can be satisfactorily applied, for example, in a field of plants.
  • the aqueous composition comprising the capsules does not contain one or more of: an active ingredient having a melting point at 25°C of less of equal to 50°C; an active ingredient in salt form, and a free or dispersed hydrophobic oil phase.
  • microencapsulated compositions of the invention can be combined with other active ingredients.
  • an aqueous composition of the present invention comprises the encapsulated lambda-cyhalothrin of the first aspect and one or more other insecticides and/or acaricides, preferably the one or more other insecticides and acaricides are not encapsulated with the pyrethroids.
  • Examples of one or more other active ingredients are from the class neonicotinoids (such as imidacloprid, acetamiprid, thiamethoxam, thiacloprid), carbamates, botanical compounds, diamides (such as chloroantraniliprole), macrocyclic lactones (such as abamectin, spinosad and emamectin), organophosphorus compounds (such as acephate), tetramic acids (such as spirotetramat), tetronic acids (such as spiromesifen, spriodiclofen) and insect growth regulators (such as lufenuron).
  • the other active ingredient is normally suspended in the aqueous composition comprising the capsules of the invention using conventional formulation techniques; as necessary further conventional formulation aids are used to prepare a stable mixture
  • an aqueous composition of the present invention comprises an encapsulated lambda-cyhalothrin of the first aspect and, as a further active ingredient, suspended thiamethoxam or suspended acetamiprid.
  • an aqueous composition of the present invention comprises encapsulated lambda-cyhalothrin of the first aspect, and, as further active ingredients, suspended thiamethoxam or suspended acetamiprid, and suspended lufenuron.
  • the d50 refers to the 50 th percentile rank, or median value, as measured on a volumetric basis by CIPAC method MT 187 for particle size analysis by laser diffraction.
  • Malven S, 2000 or 3000 instruments are the industry standard for measuring particle size by light diffraction, but similar instruments made by Cilas, Coulter-Beckman, Horiba, Sympatec and others equivalents are also acceptable.
  • a solution of lambda-cyhalothrin in SOLVESSO 200 solvent was prepared.
  • the dispersants were added followed by the titanium dioxide, and the resulting suspension agitated with a high shear stirrer. After the titanium dioxide was well dispersed, polymethylene polyphenylisocyanate and isomeric mixture of toluene diisocvanate were added to complete the organic phase.
  • This phase was introduced to the aqueous phase with agitation with a high shear stirrer to form an oil-in-water emulsion.
  • the median droplet size was about 3.0 ⁇ 1 microns.
  • the temperature was then raised to 50°C over a 30-minute period while maintaining mild agitation, and then maintained at 50°C for 3 hours.
  • the resulting suspension of microcapsules was allowed to cool to room temperature and other formulation aids, such as viscosity control agent(s), and bactericide were added and, the pH was adjusted to 5.0.
  • compositions of the present invention are suitable for control of pests by foliar application, but other applications as well, such as to soil or in or around buildings.
  • pests are sucking insects (e.g. psyllids, thrips (e.g. Thrips tabaci) stink bugs (e.g. Euschistus heros), plant hoppers and aphids (e.g. Aphis gossypii, Myzus persicae)) and chewing insects (e.g., Helicoverpa and diamondback moth (DBM), caterpillars, beetles, and slugs and snails).
  • sucking insects e.g. psyllids, thrips (e.g. Thrips tabaci) stink bugs (e.g. Euschistus heros)
  • plant hoppers and aphids e.g. Aphis gossypii, Myzus persicae
  • aphids e.g. A
  • Suitable target plants are especially potatoes, cereals, (wheat, barley, rye, oats), rice, maize, tree nuts, alfalfa, head and stem brassica (including but not limited to broccoli, cabbage, cauliflower), sugar beet, cotton, millet varieties, sorghum, tobacco, sun flowers, beans, peas, oil plants (rape, canola), soybeans, cabbages, tomatoes, eggplants (aubergines), pepper and other vegetables, and spices as well as ornamental shrubs and flowers.
  • the target crops also include transgenic crop plants of the foregoing varieties.
  • compositions of the present invention are applied at a rate per hectare, based on the active ingredient, of from 1 to 500 g/ha, such as 5 to 300g/ha, for example, 10 to 100 g/ha.
  • each formulation is a CS formulation type.
  • Tables 1 and 2 provide details of the different lambda-cyhalothrin encapsulated formulations. Each formulation in Tables 1 and 2 contained titanium dioxide in the
  • microcapsules in an amount of about 4.6% (based on the weight of the microcapsule) and had a d50 median particle size of about 0.2 to 0.4 microns.
  • Some of the encapsulated lambda-cyhalothrin formulations were then combined with thiamethoxam, or both thiamethoxam and lufenuron.
  • the 2-way (lambda-cyhalothrin & thiamethoxam) and 3-way (lambda-cyhalothrin, thiamethoxam & lufenuron) mixture formulations were of the ZC formulation type, which is a formulation containing capsules and also suspended solid particles.
  • the thiamethoxam and lufenuron were suspended in the aqueous phase and the lambda-cyhalothrin was encapsulated in the microcapsules.
  • the 2-way mixture and 3-way mixture formulated products were prepared using conventional formulating practices, such as incorporating suitable bactericides, surfactants, dispersants, antifreeze, and viscosity control agents to suspend the active ingredients and/or microcapsules and improve storage stability.
  • a sample of the CS formulation (0.30-0.35g) is weighed into a 2oz. round glass bottle. 6ml of water is then added and the sample is dispersed with gentle shaking until homogenous. Using a volumetric dispensing unit or pipette, dispense 50ml of Internal Standard (IS) (which is dicyclohexyl phthalate in hexanes at a concentration of 0.35mg/m). The bottle is then placed on a horizontal orbital shaker set to 200 ⁇ 10 rpm & a timer is started.
  • IS Internal Standard
  • Example 3 L and M were assessed against each other in the field. Each formulation was applied on soybean about ten weeks after the planting date in an amount of 200 ml/ha in separate 96m 2 randomised block plots in Brazil. The stinkbug nymphs (of the third instar and above) and adults were counted using a standardized monitoring device three, seven and ten days after application of the formulation. A plot with no treatment was also assessed for the stinkbug nymphs and adults as the check. The each trial was carried out in four replicates.
  • Certain formulations were assessed for one or more of oral toxicity, dermal toxicity, inhalation risk, skin irritation, eye irritation and skin sensitisation (LLNA) using OECD test methods indicated below in Table C.
  • Table D provides the results of the tests.
  • Comparative L contained similar components in similar amounts as Comparative K apart form a using lower amount, i.e., 0.19 wt% rather than 0.28wt%, of the anti-microbial component (PROXELTM GXL) - a 20% aqueous dipropylene glycol solution of 1 ,2-benzisothiazolin-3-one.
  • the anti-microbial component PROXELTM GXL
  • Table A1 release profile (based on weight) of Lambda-Cyhalothrin over 96 hours *
  • Example 1 Example B
  • Example C Example E
  • Example F Example G
  • Table A2 release profile (based on %) of Lambda-Cyhalothrin over 96 hours (from Table A1)
  • Example 1 Example B
  • Example C Example E
  • Example F Example G
  • Table C OECD methods used in the tests in Table D, and a brief description

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Dentistry (AREA)
  • Plant Pathology (AREA)
  • Engineering & Computer Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Agronomy & Crop Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Toxicology (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
PCT/EP2017/065541 2016-06-30 2017-06-23 Microcapsules encapsulating lambda-cyhalothrin WO2018001895A1 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
CN201780040443.5A CN109414015A (zh) 2016-06-30 2017-06-23 囊化有λ-氯氟氰菊酯的微囊剂
PL17732136.1T PL3478063T3 (pl) 2016-06-30 2017-06-23 Mikrokapsułki kapsułkujące lambda-cyhalotrynę
HRP20231633TT HRP20231633T1 (hr) 2016-06-30 2017-06-23 Mikrokapsule koje inkapsuliraju lambda-cihalotrin
EA201990133A EA201990133A1 (ru) 2016-06-30 2017-06-23 Микрокапсулы, инкапсулирующие лямбда-цигалотрин
US16/312,832 US20190350196A1 (en) 2016-06-30 2017-06-23 Microcapsules encapsulating lambda-cyhalothrin
ES17732136T ES2966395T3 (es) 2016-06-30 2017-06-23 Microcápsulas que encapsulan lambda-cihalotrina
MX2018016035A MX2018016035A (es) 2016-06-30 2017-06-23 Microcapsulas que encapsulan lambda-cihalotrina.
BR112018077181-3A BR112018077181B1 (pt) 2016-06-30 2017-06-23 Composição compreendendo microcápsulas encapsulando lambdacialotrina e método para controlar danos a plantas por pragas
EP17732136.1A EP3478063B1 (en) 2016-06-30 2017-06-23 Microcapsules encapsulating lambda-cyhalothrin
KR1020197001818A KR102513421B1 (ko) 2016-06-30 2017-06-23 람다-사이할로트린을 캡슐화하는 미세캡슐
UAA201900761A UA128382C2 (uk) 2016-06-30 2017-06-23 Мікрокапсули, що інкапсулюють лямбда-цигалотрин
PH12018502597A PH12018502597A1 (en) 2016-06-30 2018-12-10 Microcapsules encapsulating lambda-cyhalothrin
CONC2018/0013652A CO2018013652A2 (es) 2016-06-30 2018-12-17 Microcápsulas que encapsulan lambda-cihalotrina

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1611467.0A GB2551814B (en) 2016-06-30 2016-06-30 Microcapsules encapsulating lambda-cyhalothin
GB1611467.0 2016-06-30

Publications (1)

Publication Number Publication Date
WO2018001895A1 true WO2018001895A1 (en) 2018-01-04

Family

ID=56891317

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2017/065541 WO2018001895A1 (en) 2016-06-30 2017-06-23 Microcapsules encapsulating lambda-cyhalothrin

Country Status (19)

Country Link
US (1) US20190350196A1 (hr)
EP (1) EP3478063B1 (hr)
KR (1) KR102513421B1 (hr)
CN (1) CN109414015A (hr)
AR (1) AR108855A1 (hr)
BR (1) BR112018077181B1 (hr)
CL (1) CL2018003813A1 (hr)
CO (1) CO2018013652A2 (hr)
EA (1) EA201990133A1 (hr)
EC (1) ECSP18094643A (hr)
ES (1) ES2966395T3 (hr)
GB (1) GB2551814B (hr)
HR (1) HRP20231633T1 (hr)
HU (1) HUE064444T2 (hr)
MX (1) MX2018016035A (hr)
PH (1) PH12018502597A1 (hr)
PL (1) PL3478063T3 (hr)
UA (1) UA128382C2 (hr)
WO (1) WO2018001895A1 (hr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019243927A1 (en) * 2018-06-18 2019-12-26 Upl Ltd Stable co-formulation of benzoylurea with pyrethroids.

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024090965A1 (ko) * 2022-10-24 2024-05-02 주식회사 엘지화학 용출제어형 살충제를 위한 캡슐 및 이를 포함하는 용출제어형 살충제

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4285720A (en) * 1972-03-15 1981-08-25 Stauffer Chemical Company Encapsulation process and capsules produced thereby
US6133197A (en) * 1996-05-23 2000-10-17 Zeneca Limited Microencapsulated compositions
US20130115261A1 (en) * 2011-11-04 2013-05-09 Sipcam S. P. A. Use of formulations having insecticidal activity

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100313589B1 (ko) * 1993-02-09 2002-11-29 노바티스 아게 미세캡슐의 제조방법
US5846554A (en) * 1993-11-15 1998-12-08 Zeneca Limited Microcapsules containing suspensions of biologically active compounds and ultraviolet protectant
ATE197869T1 (de) * 1995-06-07 2000-12-15 Zeneca Ltd Trockene wasserdispergierbare zusammensetzungen von mikroverkapselten pestiziden
PT902724E (pt) * 1996-05-23 2002-03-28 Syngenta Ltd Composicoes microencapsuladas
CN100569073C (zh) * 2004-06-30 2009-12-16 联合磷有限公司 用于农学活性物质的安全递送系统
US20080254082A1 (en) * 2005-09-27 2008-10-16 Sol-Gel Technologies Ltd. Methods for Crop Protection
DK1840145T3 (en) * 2006-03-30 2018-02-12 Fmc Corp Microcapsules of acetylenecarbamide derivatives-polyurea polymers and controlled release formulations
CA2807456A1 (en) * 2010-08-05 2012-02-09 Makhteshim Chemical Works Ltd. Synergistic insecticidal mixtures
BR112013017684B1 (pt) * 2011-01-11 2018-12-11 Basf Se microcápsulas, método para preparar as microcápsulas, composição aquosa e método para controle de fungo fitopatogênico
CN103304772A (zh) * 2013-06-27 2013-09-18 上海永通化工有限公司 一种植物油基聚氨酯包膜、控释肥料及其制备方法
UY36002A (es) * 2014-02-19 2016-08-31 Fmc Corp Formulaciones de tratamiento de semillas encapsuladas con piretroide de alta carga
CN109691444A (zh) * 2018-12-25 2019-04-30 江苏精禾界面科技有限公司 一种pH响应型控释农药微囊悬浮剂及其制备方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4285720A (en) * 1972-03-15 1981-08-25 Stauffer Chemical Company Encapsulation process and capsules produced thereby
US6133197A (en) * 1996-05-23 2000-10-17 Zeneca Limited Microencapsulated compositions
US20130115261A1 (en) * 2011-11-04 2013-05-09 Sipcam S. P. A. Use of formulations having insecticidal activity

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019243927A1 (en) * 2018-06-18 2019-12-26 Upl Ltd Stable co-formulation of benzoylurea with pyrethroids.
CN112449572A (zh) * 2018-06-18 2021-03-05 Upl有限公司 苯甲酰脲与拟除虫菊酯的稳定共制剂

Also Published As

Publication number Publication date
EP3478063C0 (en) 2023-10-11
PH12018502597A1 (en) 2019-10-14
UA128382C2 (uk) 2024-07-03
MX2018016035A (es) 2019-05-13
CO2018013652A2 (es) 2019-01-18
EP3478063B1 (en) 2023-10-11
EP3478063A1 (en) 2019-05-08
HUE064444T2 (hu) 2024-04-28
BR112018077181B1 (pt) 2022-12-13
KR102513421B1 (ko) 2023-03-22
US20190350196A1 (en) 2019-11-21
CN109414015A (zh) 2019-03-01
PL3478063T3 (pl) 2024-03-04
GB2551814A (en) 2018-01-03
EA201990133A1 (ru) 2019-07-31
GB201611467D0 (en) 2016-08-17
ECSP18094643A (es) 2019-01-31
ES2966395T3 (es) 2024-04-22
GB2551814B (en) 2021-02-24
BR112018077181A2 (pt) 2019-04-02
KR20190022663A (ko) 2019-03-06
AR108855A1 (es) 2018-10-03
CL2018003813A1 (es) 2019-02-22
HRP20231633T1 (hr) 2024-03-15

Similar Documents

Publication Publication Date Title
US6340653B1 (en) Microencapsulated acetochlor herbicidal composition
AP926A (en) Microencapsulated Compositions
AU2006296165B2 (en) Methods for crop protection
US6133197A (en) Microencapsulated compositions
CN102123590B (zh) 用于调节微囊化的活性成分的释放速率的方法
AU2013289339B2 (en) Insecticidal formulations of microcapsules
KR20210024555A (ko) 벤조일우레아와 피레트로이드의 안정한 공동-제형물
CN101453896B (zh) 微胶囊剂
KR102513421B1 (ko) 람다-사이할로트린을 캡슐화하는 미세캡슐
HUE028469T2 (en) Agrochemical formulation, process for its preparation, and its application
JP7550707B2 (ja) マイクロカプセル農薬組成物
KR100481932B1 (ko) 마이크로캡슐화된조성물
EA040491B1 (ru) Микрокапсулы, инкапсулирующие лямбда-цигалотрин
JP2012017266A (ja) マイクロカプセル混合農薬組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17732136

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: NC2018/0013652

Country of ref document: CO

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112018077181

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20197001818

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2017732136

Country of ref document: EP

Effective date: 20190130

ENP Entry into the national phase

Ref document number: 112018077181

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20181227